ClinicalTrials.gg
RecruitingNCT06669546Updated Apr 3, 2026

Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment

An interventional study of Phase-locked auditory stimulation (PLAS) and Sham Phase-Locked Auditory Stimulation in Cognitive Decline, Alzheimer Disease and Subjective Cognitive Decline (SCD), sponsored by University of Bern. Recruiting at 1 site in Switzerland. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by University of Bern · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.

Planned enrollment
23rd of 48
60 · median 56
Started
2025
with 3 others
No phase
38 of 61
13 open now
Primary completion
2028-05
later than 17 of 20 live
Registered
50th of 61
by date
Lead sponsor
9 of 61
University of Bern

Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 23rd largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2025, is one of 38 with no phase, reaches primary completion later than 17 of the 20 other live ones, and was the 50th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cognitive Dysfunction with a site in Switzerland, or all of them as a file.
02

Study summary

This study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality. Dementia, a leading cause of death worldwide, is often associated with disturbed sleep, particularly the loss of deep, slow-wave sleep (SWS). SWS is important for memory and clearing waste from the brain. Poor SWS can worsen memory loss and allow harmful waste to build up, which may increase the risk of dementia.

The investigators are testing whether phase-locked auditory stimulation (PLAS) can improve SWS in people at a mild stage of cognitive impairment. PLAS uses short sounds played at specific moments to strengthen slow-wave brain activity during sleep. The investigators previous laboratory based research has shown that this can improve memory and help with clearing waste from the brain. Now, the investigators want to test this in a real-world setting, over a longer period, which is unfeasible in a laboratory setting.

In this study, 60 older adults will use home-use devices that deliver either real or sham (soundless) PLAS across two different 4-week periods. Memory will be tested using engaging "serious games." Before and after each experimental period, blood samples will be taken to measure dementia-related markers, and cognitive batteries will be performed. The investigators expect that PLAS will improve sleep, and that this will have a downstream effect on memory and brain clearance, potentially slowing the process of cognitive decline.

If successful, this could lead to the development of an affordable treatment that helps people maintain brain health and prevent dementia.

03

Conditions studied

  • Cognitive Decline
  • Alzheimer Disease
  • Subjective Cognitive Decline (SCD)
  • Mild Cognitive Impairment (MCI)
  • Cognitive Impairment, Mild

Keywords

  • Sleep
  • Dementia
  • Prevention
  • Phase-locked auditory stimulation
  • Blood-based biomarkers
  • Home
  • Longitudinal
  • Electroneurophysiology
  • EEG
  • Memory
  • Cognition
  • Serious games
  • Old age
  • Human
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age between 60 and 85 years
  • Cognitive impairment (subjective and/or between 23-26)
  • Native German speakers or comparably fluent
  • Normal or corrected-to-normal vision.
  • Intact hearing
  • A close cohabitant (partner/sibling) should be present to support participants in using study materials/devices.

Exclusion criteria

Exclusion Criteria:

  • Insomnia assessed by the Regensburg Insomnia Scale (RIS; Crönlein et al., 2013)
  • Restless leg syndrome assessed by questions concerning typical symptoms.
  • Sleep apnoea assessed by the Berlin Questionnaire (BQ; Netzer et al., 1999)
  • Severely irregular sleep patterns assessed by the RIS and the Pittsburgh sleep quality index (PSQI; Buysse et al., 1989)
  • Symptoms of depression (Geriatric Depression Scale (GDS; Yesavage et al., 1982) ≥ 5)
  • History of untreated severe neurological and psychiatric diseases
  • Alcohol or substance abuse
  • Use of medication acting on the central nervous system
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    PLAS first, sham second

    In this study arm, participants will undergo a 4-week intervention period with real phase-locked auditory stimulation (PLAS) administered on nights from Monday to Friday. Following this initial intervention period, participants will have a 2-week washout phase. Finally, participants will enter the second intervention period, during which sham (soundless) PLAS will be administered.

    Other: Phase-locked auditory stimulation (PLAS) · Other: Sham Phase-Locked Auditory Stimulation

  • Experimental
    Sham first, PLAS second

    In this study arm, participants will undergo a 4-week intervention period with sham (soundless) phase-locked auditory stimulation (PLAS) administered on nights from Monday to Friday. Following this initial intervention period, participants will have a 2-week washout phase. Finally, participants will enter the second intervention period, during which real PLAS will be administered.

    Other: Phase-locked auditory stimulation (PLAS) · Other: Sham Phase-Locked Auditory Stimulation

Interventions

  • OtherPhase-locked auditory stimulation (PLAS)

    Intervention: Verum Phase-Locked Auditory Stimulation (PLAS) Using the SleepLoop Device. The experimental intervention utilizes the SleepLoop device, a home-use, EEG-based system designed for phase-locked acoustic stimulation (PLAS). The device continuously monitors sleep through EEG (Fpz) alongside electrooculogram (EOG) and electromyogram (EMG) channels. The device employs a closed-loop algorithm that detects slow oscillations (SOs) in the EEG and delivers short sound stimuli (50 ms pink noise) during the positive half-waves of slow waves in slow-wave sleep (SWS). These stimuli are delivered through integrated headphones in the SleepLoop device. The intervention is applied during work days for 4 weeks. The algorithm is only active during SWS and does not deliver stimuli when the participant is awake, or in lighter sleep stages (N1, N2) or REM sleep. The intensity and algorithm sensitivity are individually calibrated for each participant to optimize stimulation.

    Also known as: Acoustic stimulation, Phase-targeted auditory stimulation (PTAS), Auditory stimulation, Closed-loop acoustic stimulation

  • OtherSham Phase-Locked Auditory Stimulation

    Participants will undergo the same procedure as the real Phase-Locked Auditory Stimulation (PLAS) intervention. However, during the sham condition, the headphones are turned off, and no auditory stimulation is delivered.

06

What researchers measure

Primary outcomes

  1. Episodic memory performance differences (between and within subject) according to the experimental condition

    Episodic memory performance will be assessed by means of serious games.

    Time frame: Participants will play serious games on weekdays during the adaptation week, as well as on weekdays throughout both the first and second 4-week intervention periods.

Secondary outcomes

  1. Electrophysiological Response - Event-Related Potentials (ERPs)

    Electrophysiological responses will be measured via EEG to assess event-related potentials (ERPs) in response to real versus sham acoustic stimulation.

    Time frame: Sleep-Electrophysiology will be measured on weekdays during the adaptation week, as well as on weekdays throughout both the first and second 4-week intervention periods.

  2. Electrophysiological Response - Power, Number, and Amplitude of Slow Oscillations (SO) and Spindles

    Electrophysiological responses will be measured via EEG to assess the power, number, and amplitude of slow oscillations (SO) and sleep spindles in response to real versus sham acoustic stimulation.

    Time frame: Sleep-electrophysiology will be measured on weekdays during the adaptation week, as well as on weekdays throughout both the first and second 4-week intervention periods.

  3. Electrophysiological Response - Coupling of Slow Oscillations and Sleep Spindles

    Electrophysiological responses will be measured via EEG to assess the coupling between slow oscillations and spindles in response to real versus sham acoustic stimulation.

    Time frame: Sleep-electrophysiology will be measured on weekdays during the adaptation week, as well as on weekdays throughout both the first and second 4-week intervention periods.

  4. Amyloid-Beta Response

    Blood samples will be collected to measure plasma amyloid-beta levels and compare them across conditions.

    Time frame: At baseline, after 4 weeks, after 6 weeks, after 10 weeks

  5. Electrophysiology - Brain Age Estimation

    EEG, EMG, and ECG will be used to estimate brain age and assess whether PLAS leads to a rejuvenation of the brain, reflecting a younger brain state. Machine learning will analyze sleep-EEG data to provide an accurate brain age estimate.

    Time frame: Sleep electrophysiology will be measured on weekdays during the adaptation week and on weekdays throughout both the first and second 4-week intervention periods.

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Old Age Psychiatry and Psychotherapy, University of Bern
    Bern, 3000 60, Switzerland
    Recruiting
08

References and documents

Publications

  • Lustenberger C, Ferster ML, Huwiler S, Brogli L, Werth E, Huber R, Karlen W. Auditory deep sleep stimulation in older adults at home: a randomized crossover trial. Commun Med (Lond). 2022 Apr 4;2:30. doi: 10.1038/s43856-022-00096-6. eCollection 2022. PubMed 35603302 ↗
  • Wunderlin M, Zust MA, Hertenstein E, Feher KD, Schneider CL, Kloppel S, Nissen C. Modulating overnight memory consolidation by acoustic stimulation during slow-wave sleep: a systematic review and meta-analysis. Sleep. 2021 Jul 9;44(7):zsaa296. doi: 10.1093/sleep/zsaa296. PubMed 33406249 ↗
  • Zeller CJ, Wunderlin M, Wicki K, Teunissen CE, Nissen C, Zust MA, Kloppel S. Multi-night acoustic stimulation is associated with better sleep, amyloid dynamics, and memory in older adults with cognitive impairment. Geroscience. 2024 Dec;46(6):6157-6172. doi: 10.1007/s11357-024-01195-z. Epub 2024 May 14. PubMed 38744792 ↗
  • Wunderlin M, Zeller CJ, Senti SR, Feher KD, Suppiger D, Wyss P, Koenig T, Teunissen CE, Nissen C, Kloppel S, Zust MA. Acoustic stimulation during sleep predicts long-lasting increases in memory performance and beneficial amyloid response in older adults. Age Ageing. 2023 Dec 1;52(12):afad228. doi: 10.1093/ageing/afad228. PubMed 38163288 ↗

Individual participant data

Plan to share: No — Currently, there are no collaborations to disclose, but the investigators are generally open to such endeavours in the future. For this purpose, general consent for reuse of data is being collected from participants.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2028, 39 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 39 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 1, 2024
StartActual
Feb 21, 2025
Primary completionEst.
May 2028
CompletionEst.
Dec 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669546
Lead sponsor
University of Bern
Collaborators
University of Zurich, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Feb 21, 2025
Primary completion
May 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Marc A Züst, PhD
Contact
marc.a.zuest@unibe.ch
+41 (0)58 630 95 02
Korian Wicki, Master
Contact
korian.wicki@unibe.ch
+41 76 605 24 00
Marc A Züst, PhD
principal investigator · University Hospital of Old Age Psychiatry and Psychotherapy, University of Bern, 3000 Bern, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion